Olema Pharmaceuticals Inc
OLMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$928.5M
Close$
$0.54
94.8% downside
Current Fair Value
94.8% downsideOvervalued by 94.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $928.50 Million |
|---|---|
| Enterprise Value | $880.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.87 |
| Beta | 2.01 |
| Outstanding Shares | 104,453,732 |
Return
| Return on Equity | -47.51% |
|---|---|
| Return on Assets | -42.04% |
| Return on Invested Capital | -49.24% |
Valuation & Multiples
| P/E Ratio | -5.01 |
|---|---|
| PEG | -11.31 |
| Price to Sales | - |
| Price to Book Ratio | 2.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.12 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.03% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.26%▼ 103.36% |
|---|---|
| Total Invested | $170.52M▼ 88.73% |
| Investors Holding | 45▼ 174.00% |
ESG Score
No data
About Olema Pharmaceuticals Inc
37 employeesOlema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an o...